[1]牛春华 张杉杉 刘国庆.骨髓增生异常综合征铁超载致糖尿病1例并文献复习[J].国际内分泌代谢杂志,2019,39(06):426-428.[doi:10.3760/cma.j.issn.1673-4157.2019.06.016]
　Niu Chunhua,Zhang Shanshan,Liu Guoqing.Diabetes caused by iron overload in myelodysplastic syndrome: one case report and literatures review[J].International Journal of Endocrinology and Metabolism,2019,39(06):426-428.[doi:10.3760/cma.j.issn.1673-4157.2019.06.016]

点击复制

骨髓增生异常综合征铁超载致糖尿病1例并文献复习()

分享到：

参考文献/References:

[1] Mitchell M,Gore SD,Zeidan AM.Iron chelation therapy in myelodysplastic syndromes: where do we stand?[J].Expert Rev Hematol,2013,6(4):397-410.DOI:10.1586/17474086.2013.814456.
[2] Petrou E,Mavrogeni S,Karali V,et al.The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes[J].Rev Bras Hematol Hemoter,2015,37(4):252-258.DOI:10.1016/j.bjhh.2015.03.014.
[3] Wilson JG,Lindquist JH,Grambow SC,et al.Potential role of increased iron stores in diabetes[J].Am J Med Sci,2003,325(6):332-339.DOI:10.1097/00000441-200306000-00004.
[4] 李云双,聂伟业,黄琴,等.强化去铁治愈重型地中海贫血铁超载并糖尿病一例[J].中国糖尿病杂志,2017,25(7):659-661.DOI:10.3969/j.issn.1006-6187.2017.07.018.
[5] Shenoy N,Vallumsetla N,Rachmilewitz E,et al.Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome[J].Blood,2014,124(6):873-881.DOI:10.1182/blood-2014-03-563221.
[6] Porter JB,El-Alfy M,Viprakasit V,et al.Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment[J].Eur J Haematol,2016,96(1):19-26. DOI:10.1111/ejh.12540.
[7] Takatoku M,Uchiyama T,Okamoto S,et al.Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality[J].Eur J Haematol,2007,78(6):487-494.DOI:10.1111/j.1600-0609.2007.00842.x.
[8] Yassin MA,Soliman A,De Sanctis V,et al. The impact of iron overload in patients with acute leukemia and myelodysplastic syndrome on hepatic and endocrine functions[J].Acta Biomed,2018,89(3-S):18-22.DOI:10.23750/abm.v89i3-S.7213.
[9] Swaminathan S,Fonseca VA,Alam MG,et al. The role of iron in diabetes and its complications[J]. Diabetes Care,2007,30(7):1926-1933.DOI:10.2337/dc06-2625.
[10] Simcox JA,McClain DA.Iron and diabetes risk[J].Cell Metab,2013,17(3):329-341.DOI:10.1016/j.cmet.2013.02.007.
[11] Huang J,Jones D,Luo B,et al.Iron overload and diabetes risk: a shift from glucose to fatty acid oxidation and increased hepatic glucose production in a mouse model of hereditary hemochromatosis[J].Diabetes,2011,60(1):80-87.DOI:10.2337/db10-0593.
[12] Mainous AG 3rd,Tanner RJ,Hulihan MM,et al. The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome[J].Br J Haematol,2014,167(5):720-723.DOI:10.1111/bjh.13053.
[13] Neukirchen J.Iron chelation in MDS:still a controversial issue[J].Leuk Res,2014,38(2):145-146.DOI:10.1016/j.leukres.2013.12.004.